›› 2018, Vol. 38 ›› Issue (7): 797-.doi: 10.3969/j.issn.1674-8115.2018.07.015

• Review • Previous Articles     Next Articles

Mechanism of differences in prolactin levels in patients with schizophrenia after antipsychotics treatment

LI Yan-ge1, YU Wen-juan1, SHEN Yi-feng1, LI Hua-fang2, 3   

  1. 1. Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; 2. Shanghai Key Laboratory of Psychotic Disorders, Shanghai 200030, China; 3. Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
  • Online:2018-07-28 Published:2018-07-30
  • Supported by:
    National Major Project for Investigational New Drug, 2018ZX09734-005; Multi-center Clinical Study Project of Shanghai Jiao Tong University School of Medicine, DLY201620; Project of Collaborative Innovation center for Translational Medicine at Shanghai Jiao Tong University School of Medicine,TM201624

PDF (PC)

700

Abstract: Antipsychotics have been the mainstay of schizophrenia treatment, but the frequency of adverse reactions (ARs) related with antipsychotics usage is high. Of all the ARs, hyperprolactinemia is relatively common and the controversy over it remains ongoing, as different patients manifest different prolactin levels and different clinical syndromes. Into understand this heterogeneity, this review stated the mechanisms underlying the different prolactin levels in schizophrenia patients after antipsychotics treatment, including the ability to block dopamine D2 receptor (DRD2), the influence on blood-brain barrier permeability, varying affinity toDRD2, the inhibition/excitatory effect on DRD2andgeneticpolymorphisms.

Key words: prolactin, schizophrenia, antipsychotics

CLC Number: